Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 60

Sponsor: Università degli Studi 'G. d'Annunzio' Chieti e Pescara

Location: Dipartimento di Medicina e Scienze dell'Invecchiamento, Università degli Studi "G. d'Annunzio" di Chieti - Pescara Chieti CH

Summary

A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed/refractory multiple myeloma.

Eligibility Criteria

Inclusion Criteria: * patients diagnosed with relapsed/refractory multiple myeloma according to IMWG criteria who have undergone allogeneic hematopoietic stem cell transplantation; * Age ≥ 18 years; * Signature of the informed consent form (where possible). Exclusion Criteria: * Patients diagnosed with primary AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), indolent multiple myeloma, or primary plasma cell leukemia; * Patients who have not undergone allogeneic hematopoietic stem cell transplantation; * Age \< 18 years.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07777406). StuddyBuddy aggregates publicly available trial information.